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Resumo 
Introdução e objectivo: O estudo da expressão dos 
marcadores CD44/CD24 e ALDH1  é o mais frequentemente utilizado 
para identificar o fenótipo estaminal (ou stem) nos carcinomas da mama, 
tendo a maioria desses estudos sido realizada em amostras de carcinomas 
ductais invasores. Assim, a prevalência e o significado clinico do fenótipo 
stem nos carcinomas de tipos histológicos especiais, permanecem 
desconhecidos. Por conseguinte, o objectivo deste estudo é determinar a 
distribuição dos marcadores stem no carcinomas de mama de tipo 
histológico especial. 
Métodos: Foi analisada a expressão de CD44, CD24 e ALDH1 em 117 
amostras de carcinomas da mama de tipo histológico especial, tendo os 
resultados obtidos sido comprados com uma série de 466 carcinomas 
ductais invasores. 
Resultados: Os tipos histológicos especiais demonstraram uma maior 
prevalência de células neoplásicas com expressão CD44+ (78.2% Vs. 
51.2%; p<0.001) e maior prevalência do fenótipo  CD44
+
/CD24
-/low
 (65.5% 
Vs. 45.3; p<0.001) e CD44
+
/CD24
-/low
/ALDH1
+
 (11.5% Vs. 4.8; p=0.043), 
quando comparados com os carcinomas ductais invasores. Todos os 
marcadores mostraram diferenças significativas dentro do grupo dostipos 
especiais com os carcinomas. Os carcinomas medulares e metaplásicos 
demonstrarem um significativo enriquecimento no fenótipo CD44
+
/CD24
-
/low
/ALDH1
+
 . 
Conclusões: Os tipos histológicos especiais não são homogéneos em 
relação à expressão dos marcadores de células stem cancerígenas  
diferindo também neste aspecto dos carcinomas ductais invasores. 
Utilizando o painel de marcadores de células stem cancerígenas 
CD44
+
/CD24
-/low
/ALDH1
+
 fomos capazes de, dentro dos tipos especiais, 
distinguir os carcinomas medulares e metaplásicos, dois tipos histológicos 
associados a alto grau histológico e fenótipo de tipo basal. 
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Abstract 
BACKGROUND AND AIM: The study of CD44/CD24 and ALDH1 expression is the most consistently used 
to identify cancer stem cells (CSC) phenotype on breast cancer. Most of these studies were performed 
using invasive ductal carcinomas (IDCs) samples. It is largely unknown the prevalence and clinical 
significance of the CSC phenotypes defined by these markers in breast cancer special histological types. 
Therefore, the aim of this study is to determine the breast CSC markers distribution among special 
histological types of breast cancer. 
METHODS: 117 invasive special type breast carcinomas were analysed for the expression of CD44, CD24 
and ALDH1, to evaluate their distribution among the distinct special type and the results were compared 
to a series of 466 IDCs. 
RESULTS: When comparing with IDC’s, special histological subtypes group displayed higher prevalence 
of CD44
+
 cells (78.2% Vs. 51.2; p<0.001) and higher prevalence of the CSC phenotypes CD44
+
/CD24
-/low
  
(65.5% Vs. 45.3; p<0.001) and CD44
+
/CD24
-/low
 /ALDH1
+
 (11.5% Vs. 4.8%; p=0.043). All markers displayed 
significant differences within the special subtypes group with medullary and metaplasic carcinomas 
displaying a significant enrichment in the CD44
+
/CD24
-/low
/ALDH1
+
 phenotype. 
CONCLUSIONS: Special histological types of breast carcinomas are not homogeneous in CSC markers 
expression and differ from IDCs. With the use of a panel of CSC markers that defined the CSC phenotype 
CD44
+
/CD24
-/low
/ALDH1
+
, we were able to within special types distinguish medullary and metaplasic 
carcinomas, two histological types associated with high grade and basal-like phenotype. 
 
Key words:  Breast Cancer; Histological special types; CD44/CD24/ALDH1; Cancer Stem 
Cells 
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Introduction 
Breast cancer is nowadays a leading cause of cancer death among women and recognized as a complex 
and heterogeneous disease, comprised of various histological subtypes, with variable clinical 
presentations and different underlying molecular signatures 
1
.  
The histological diversity of adenocarcinomas in the breast has long fascinated pathologists. Most 
invasive breast cancers are classified as invasive ductal carcinoma not otherwise specified (IDC-NOS), 
whereas about 25% are histologically defined as 'special types' 
1,2
, a group that encompasses many 
morphological distinct subtypes, like medullary, mucinous, papillary, micropapillary, tubular, among 
others, being the distinction between these subgroups made based on morphological criteria. 
Although special types of breast cancer have been shown to be associated with distinct biological 
features and carry important clinical implications (e.g. patients with tubular carcinomas have survival 
rates close to normal life expectancy 
3
, the use of information on special types has been limited in 
tailoring the therapy for breast cancer patients. More and more therapy decision-making is governed by 
a molecular classification of breast cancer, curiously, this classification was derived mainly from the 
analysis of IDC-NOS samples and therefore it is unknown whether this classification applies to all 
histological subtypes
4,5
.  
Nevertheless, in recent years it has become apparent that the histopathological characteristics of these 
cancers may be underpinned by distinct arrays of genetic changes, providing direct evidence for 
genotypic-phenotypic correlations
6
 between morphological patterns and molecular changes 
in breast cancer like t(12;15)(p13;q25) ETV6–NTRK3 fusion gene in secretory carcinomas
7 
or the 
t(6;9)(q22–23; p23–24) MYB–NFIB fusion gene in adenoid cystic carcinomas
8
. 
For these reasons, proper pathological evaluation may effectively support and allow more accurate 
definition of prognosis and treatment choice in niches of patients diagnosed with special types of breast 
cancer 
9
. 
Despite our increased knowledge about this disease and combined treatment with surgery, 
radiotherapy, chemotherapy and “targeted”-therapies, many breast cancer patients will ultimately 
develop metastatic disease. One theory that could (at least partially) explain treatment failure is the 
cancer stem cell (CSC) theory. This theory postulates that cancer may be originated and sustained by a 
small proportion of stem-like cells that display the ability to main tumour growth by self-renewal and 
differentiation
10 
and also display resistance to chemo 
11
 and radiotherapy 
12
. 
Specifically regarding breast cancer, many studies have attempted to demonstrate the presence of 
breast CSC (BCSC) based on cell surface marker profiles being the phenotype CD44
+
/CD24
-/low
  the most 
consistently associated with cells displaying BCSC characteristics
13,14
. The presence of aldehyde 
dehydrogenase activity (ALDH) has also been associated with CSC characteristics. Breast cancer cases 
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presenting ALDH1
+
 phenotype are more resistant to platinum-based chemotherapy, more aggressive 
and associated with worse prognosis
15-18
. 
Some authors have also investigated the significance of combining both phenotypes and it has been 
shown that ALDH1 expression can further divide CD44
+
/CD24
-/low
 cell population
19 
having similar findings 
been reported by our group in a recent study
20
. In the same study, we also demonstrate that 
CD44
+
/CD24
-/low
 and ALDH1
+ 
phenotypes are associated with basal-like tumors both in-vitro and in-
vivo
20
. 
Based on current knowledge, there is evidence to support the idea that the use of CD44 and CD24 cell 
surface markers in combination with ALDH1 activity is the most accurate method to identify and isolate 
CSC-like cells within breast invasive ductal carcinoma (IDC). Regarding special breast cancer 
morphological subtypes, to our knowledge, only few studies have been conducted exploring the role of 
CD44 and CD24 in micropapillary carcinoma of the breast
21-23
. Even in a recent study by Park et al. in 
which several stem cell-related markers have been tested, only ductal carcinoma samples were used
24.
 
Others have used cohorts of mainly composed of IDC-NOS with only few cases of special subtypes
19,25
. 
Therefore, the presence of CSC phenotype in the special breast cancer morphological subtypes remains 
largely unknown. 
In the present study, we analyzed the immunohistochemical expression distribution of the main 
established breast CSC markers, namely CD44, CD24 and ALDH1, in a series of special histological 
subtypes of breast carcinomas. In addition, we investigated the correlation between the presence of 
these markers and the available clinicopathological features. Finally, we compared obtained results with 
a large series of IDC-NOS where the presence of this BCSC had already been investigated by our group
20
 
in order to determine whether exists significant differences in the prevalence of CSC phenotypes 
between IDC-NOS and special histological subtypes. 
 
Material and methods 
 
Breast tumour samples 
Formalin-fixed, paraffin-embedded tissues of 117 invasive special type breast carcinomas were 
consecutively retrieved from the histopathology files of private Laboratory of Pathology in Campinas, 
São Paulo, Brazil. This series contained cases of the following special type: 5 lobular classic and 2 
pleomorphic, 16 tubular, 26 mucinous, 6 micropapillary, 8 invasive papillary, 4 typical and 16 atypical 
medullary, 10 metaplastic and 24 apocrine carcinomas. All cases were reviewed on hematoxylin and 
eosin-stained (H&E) sections by two pathologists (RG and FS). 
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TMA construction 
Representative tumour areas were selected on H&E sections and marked on paraffin blocks. Two tissue 
cores (2mm in diameter) were obtained from each specimen and deposited into a recipient paraffin 
block using a TMA workstation (TMA builder 20010.02, Histopathology Ltd., Hungary). Fourteen TMA 
blocks were constructed, each one containing 24 tissue cores, arranged in a 4 x 6 sector. In each TMA 
block, normal breast and testicular tissue were included as controls. After construction, 2µm tissue 
sections were cut and adhered to glass slides (Polysine 
TM
, Menzel-Glasser, Germany) for the 
immunohistochemical studies and a H&E-stained section from each TMA block was reviewed in order to 
confirm the presence of morphological representative areas of the original lesions. 
Immunohistochemistry 
In order to classify all breast cancer tumours molecularly, we evaluated the expression of some 
commonly used breast cancer biomarkers, namely the hormonal receptors ER and PgR, the proliferation 
marker Ki67, the tyrosine kinase receptors HER2 and EGFR, CK5 and also P-cadherin. 
Immunohistochemistry was performed in 3 mm sections. To study CSC markers in this series, specific 
antibodies for CD44 (clone 156-3C11; Cell Signaling Technology, Danvers, Massachusetts, USA), CD24 
(clone Ab2-SN3b; Neomarkers, Fremont, California, USA) and ALDH1 (clone EP1933Y; Abcam, 
Cambridge, Massachusetts, USA) were used. The primary antibodies were detected using a secondary 
antibody with horseradish peroxidase polymer (Cytomation Envision System HRP; DAKO, Carpinteria, 
California, USA), or a biotinylated goat anti-polyvalent as secondary antibody, followed by the 
streptavidin-peroxidase complex (Thermo Fisher Scientific, Fremont, California, USA), according to the 
manufacturer’s instructions. Both methods used diaminobenzidine as chromogen. Detailed conditions 
for each antibody can be found in supplementary table S1. 
Immunohistochemistry evaluation 
The expression of the breast cancer biomarkers ER, PgR, HER2, EGFR, CK5 and P-cadherin was evaluated 
according to the grading systems already described
26
. 
In order to compare our results with previously published studies, CD44, CD24 and ALDH1 was 
evaluated and scored as previously published
20
. Briefly, CD44 and CD24 staining were detected mainly at 
the membrane of tumour cells and the scoring was considered as follows: 0, 0-10% of positive tumour 
cells; 1+, 10-25% of positive tumour cells; 2+, 25-50% of positive tumour cells; 3+, more than 50% of 
positive tumour cells. Cytoplasmic staining was not considered for any of these markers. For CD44, the 
cases classified as 0 were considered negative, whereas 1+, 2+ and 3+ were established as positive 
cases. For CD24, the cases were divided into negative/low, when considered 0 or 1+, or in positive cases, 
when classified as 2+ or 3+. Immunohistochemical staining of ALDH1 was classified as positive when 
more than 1% of tumour cells showed clear cytoplasmic positivity, as previously described
15,18
. 
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Statistical Analysis 
Associations between the CD44, CD24, ALDH1 expression and the different molecular subtypes, the 
clinicopathological parameters or the different molecular markers were assessed using the χ
2
 test or 
Fisher’s exact test when appropriate. Statistical analyses were carried out using SPSS statistics version 
20.0 software and a two-tailed significance level of 5% was considered as statistically significant. 
 
Results 
 
Association between the expression of CD44, CD24 and ALDH1 with other breast cancer parameters 
The expression of CD44, CD24 and ALDH1 was analysed in all breast cancer cases with adequate sample 
of tumour after TMA’s revision. 
The expression of CD44 was analysed in 87 cases and 78.2% (68/87) demonstrated clear positive 
membrane staining. In contrast, membrane CD24 was classified as negative/low in the majority of the 
cases (81.1%, 73/90). Concerning ALDH1, 13.3% (8/60) were considered positive, showing clear 
cytoplasmic expression in tumour cells.  
When CD44, CD24 and ALDH1 were associated with classic prognostic factors, as well as with other 
biomarkers studied, CD44 expression was not significantly associated with any of the available variables. 
In contrast, a significant correlation between CD24 expression and high grade tumours was found, as 
58.8% (10/17) of the positive cases were grade III (p=0.011), as well as with absence of ER expression 
and with HER2 overexpression (table I). CD24 was also correlated with the immunohistochemical 
molecular subtypes, being the majority of luminal carcinomas classified as CD24
-/low 
(90.2%; 55/60). 
In case of ALDH1 expression, it was significantly associated with high grade tumours (p=0.025), ER 
negativity (p=0.010), PgR negativity (p=0.022) and with basal marker expression, namely EGFR 
(p=0.014), CK5 (p=0.013) and P-cadherin (p<0.016). ALDH1 expression was also associated with triple-
negative tumours (p=0.010).  
 
CSC phenotype markers and association with breast cancer parameters 
To further explore the association between tumours characteristics and the CSC phenotypes, we 
decided to consider a tumour with CSC phenotype when the frequency of CD44
+
/CD24
−/low
 cells were 
more than 10% as previously described in other studies
14,27
. Similarly to the approach by Raza Ali H et 
al.
19
, and following our previous findings
20
 we further defined a putative CSC phenotype by adding the 
ALDH1 expression in more than 1% of tumour cells condition to the previous phenotype CD44
+
/CD24
-/low
 
(in more than 10% of tumour cells), thus defining a CD44
+
/CD24
-/low
/ALDH1
+
 phenotype. The phenotype 
CD44
+
/CD24
−/low
 was observed in 65.5% (57/87) whereas the phenotype CD44
+
/CD24
-/low
/ALDH1
+
 was 
observed in 11.5% (6/52) of the tumours (table II). 
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When these phenotypes were correlated with pathological variables and biomarkers, in our special 
subtypes breast carcinoma series, the phenotype CD44
+
/CD24
-/low
 was significantly associated with 
negative HER2  status (p=0.018) and high grade (p=0.005). As for the CD44
+
/CD24
-/low
/ALDH1
+
 
phenotype it was correlated with ER and PgR negativity (p=0.008 and p=0.009, respectively) and with 
the presence of basal markers, namely EGFR (p=0.022) and CK5 (p=0.001) (table II).  
The CD44
+
/CD24
-/low
/ALDH1
+
 phenotype was further associated with triple-negative tumours in 
comparison with luminal ones (p=0.008) (table II). 
 
Table I - Associations between the expression of the breast cancer stem cell markers CD44, CD24 and 
ALDH1 and the classic breast cancer prognostic factors, biological markers and molecular subtypes 
CD44       CD24       ALDH1     
  n Positive (a) Negative (a) p Value   n Positive (a) Neg/low (a) p Value   n Positive (a) Negative (a) p Value 
Histological grade 87 68 (78.2) 19 (21.8) 0.092 
 
90 17 (18.9) 73 (81.1) 0.011 
 
60 8 (13.3) 52 (86.7) 0.025 
Grade I 33 28 (84.8) 5 (15.2) 
  
33 1 (3.0) 32 (97.0) 
  
24 0 (0.0) 24 (100.0) 
 
Grade II 17 10 (58.8) 7 (41.2) 
  
18 6 (33.3) 12 (66.7) 
  
14 2 (14.3) 12 (85.7) 
 
Grade III 37 30 (81.1) 7 (18.9) 
  
39 10 (25.6) 29 (74.4) 
  
22 16 (72.7) 6 (27.3) 
 
ER 87 68 (78.2) 19 (21.8) 0.615 
 
90 17 (18.9) 73 (81.1) 0.009 
 
60 8 (13.3) 52 (86.7) 0.010b 
Positive 60 46 (76.7)  14 (23.3) 
  
61 7 (11.5) 54 (88.5) 
  
41 2 (4.9) 39 (95.1) 
 
Negative 27 22 (81.1) 5 (18.5) 
  
29 10 (34.5) 19 (65.5) 
  
19 6 (31.6) 13 (68.4) 
 
PgR 87 68 (78.2) 19 (21.8) 0.667 
 
90 17 (18.9) 73 (81.1) 0.363 
 
59 8 (13.6) 51 (86.4) 0.022b 
Positive 45 36 (80.0) 9 (20.0)  
  
46 7 (15.2) 39 (84.8) 
  
31 1 (3.2) 30 (96.8) 
 
Negative 42 32 (76.2) 10 (23.8) 
  
44 10 (22.7) 34 (77.3) 
  
28 7 (25.0) 21 (75.0) 
 
HER2 87 68 (78.2) 19 (21.8) 0.364a 
 
90 17 (18.9) 73 (81.1) 0.005b 
 
60 8 (13.3) 52 (86.7) 0.133b 
Positive 8 5 (62.5) 3 (37.5) 
  
8 5 (62.5) 3 (37.5) 
  
1 1 (100.0) 0 (0.0) 
 
Negative 79 63 (79.7) 16 (20.3) 
  
82 12 (14.6) 70 (85.4) 
  
59 7 (11.9) 52 (88.1) 
 
Ki67 81 62 (76.5) 19 (23.5) 0.925 
 
84 15 (17.9) 69 (82.1) 0.101b 
 
57 7 (12.3) 50 (87.7) 0.660
b
 
Positive 59 45 (76.3) 14 (23.7) 
  
62 14 (22.6) 48 (77.4) 
  
41 6 (14.6) 35 (85.4) 
 
Negative 22 17 (77.3) 5 (22.7) 
  
22 1 (4.5) 21 (95.5) 
  
16 1 (6.3) 15 (93.8) 
 
EGFR 86 67 (77.9) 19 (22.1) 0.542a 
 
89 16 (18.0) 73 (82.0) 0.469 
 
59 8 (13.6) 51 (86.4) 0.014
b
 
Positive 20 17 (85.0)  3 (15.0) 
  
20 4 (20.0) 16 (80.0) 
  
14 5 (35.7) 9 (64.3) 
 
Negative 60 50 (75.8) 16 (24.2) 
  
69 12 (17.4) 57 (82.6) 
  
45 3 (6.7) 42 (93.3) 
 
CK5 86 67 (77.9) 19 (22.1) 0.439 
 
89 17 (19.1) 72 (80.9) 0.459 
 
60 8 (13.3) 52 (86.7) 0.013
b
 
Positive 29 24 (82.8) 5 (17.2) 
  
30 7 (23.3) 23 (76.7) 
  
20 6 (30.0) 14 (70.0) 
 
Negative 57 43 (75.4) 14 (24.6) 
  
59 10 (16.9) 49 (83.1) 
  
40 2 (5.0) 38 (95.0) 
 
P-cadherin 86 67 (77.9) 19 (22.1) 0.795 
 
89 17 (19.1) 72 (80.9) 0.166 
 
59 8 (13.6) 51 (86.4) 0.016
b
 
Positive 52 41 (78.8) 11 (21.2) 
  
55 13 (23.6) 42 (76.4) 
  
35 8 (22.9) 27 (77.1) 
 
Negative 34 26 (76.5) 8 (23.5) 
  
34 4 (11.8) 30 (30.2) 
  
24 0 (0.0) 24 (100.0) 
 
Molecular subtypes 87 68 (78.2) 19 (21.8) 0.262 
 
90 17 (18.9) 73 (81.1) 0.004 
 
60 8 (13.3) 52 (86.7) 0.010b 
Luminal 60 45 (75.0) 15 (25.0) 
  
60 6 (9.8) 55 (90.2) 
  
41 2 (4.9) 39 (95.1) 
 
HER2-OE 6 4 (66.7) 2 (33.3) 
  
6 3 (50.0) 3 (50.0) 
  
- - - 
 
Triple-negative 21 19 (90.5) 2 (9.5)     23 8 (34.8) 15 (65.2)     19 6 (31.6) 13 (68.4)   
a Percentage of row total 
b
 Two-sided Fisher's exact test 
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Breast cancer special subtypes and CSC phenotype markers 
Our special breast cancer subtypes series was composed of 9 morphological subtypes that were 
condensed in 8 categories, since classic lobular and lobular pleomorphic were classified as “lobular”. 
Therefore, our series was composed of:  22.2% mucinous (26/117), 17.1% medullary (20/117), 13.7% 
tubular (16/117), 20.5% invasive apocrine (24/117), 6.0% lobular (7/117), 8.5% metaplasic (10/117), 
5.1% micropapillary (6/117) and 6.8% papillary (8/117) breast invasive carcinomas. 
 
Table II - Associations between the expression of the breast cancer stem cell markers phenotypes 
CD44
+
/CD24
-/low
, CD44
+
/CD24
-/low
/ALDH1
+
 the breast cancer prognostic factors, biological markers and 
molecular subtypes 
 
CD44/CD24 
        
CSC phenotype 
(CD44/CD24/ALDH1)   
  n 
CD44+/CD24-/low 
>10% (a) 
CD44+/CD24-/low 
<10% (a) p Value   n Present (
a) Absent (a) p Value 
Histological grade 87 57 (65.5) 30 (34.5) 0.005 
 
52 6 (11.5) 46 (88.5) 0.064 
Grade I 33 27 (81.8) 6 (18.2) 
  
23 0 (0.0) 23 (100.0) 
 
Grade II 17 6 (35.3) 11 (64.7) 
  
11 2 (18.2) 9 (81.8) 
 
Grade III 37 24 (64.9) 13 (35.1) 
  
18 4 (22.2) 14 (77.8) 
 
ER 87 57 (65.5) 30 (34.5) 0.410 
 
52 6 (11.5) 45 (88.5) 0.008
b
 
Positive 60 41 (68.3) 19 (31.7) 
  
36 1 (2.8) 35 (97.2) 
 
Negative 27 16 (59.3) 11 (40.7) 
  
16 5 (31.3) 11 (68.8) 
 
PgR 87 57 (65.5) 30 (34.5) 0.493 
 
52 6 (11.5) 46 (88.5) 0.009
b
 
Positive 45 31 (68.9) 14 (31.1) 
  
27 0 (0.0) 27 (100.0) 
 
Negative 42 26 (61.9) 16 (38.1) 
  
25 6 (24.0) 19 (76.0) 
 
HER2 87 57 (65.5) 30 (34.5) 0.018b 
 
52 6 (11.5) 46 (88.5) 1.000
b
 
Positive 8 2 (25.0) 6 (75.0) 
  
1 0 (0.0) 1 (100.0) 
 
Negative 79 55 (69.6) 24 (30.4) 
  
51 6 (11.8) 45 (88.2) 
 
Ki67 81 53 (65.4) 28 (34.6) 0.399 
 
49 5 (10.2) 44 (89.8) 1.000
b
 
Positive 59 37 (62.7) 22 (37.3) 
  
36 4 (11.1) 32 (88.9) 
 
Negative 22 16 (72.7) 6 (27.3) 
  
13 1 (7.7) 12 (92.3) 
 
EGFR 86 57 (66.3) 29 (33.7) 0.688 
 
51 6 (11.8) 45 (88.2) 0.022
b
 
Positive 20 14 (70.0) 6 (30.0) 
  
12 4 (33.3) 8 (66.7) 
 
Negative 66 43 (65.2) 23 (34.8) 
  
39 2 (5.1) 37 (94.9 
 
CK5 86 56 (65.1) 30 (34.9) 0.956 
 
52 6 (11.5) 46 (88.5) 0.001
b
 
Positive 29 19 (65.5) 10 (34.5) 
  
17 6 (35.3) 11 (64.7) 
 
Negative 57 37 (64.9) 20 (35.1) 
  
35 0 (0.0) 35 (100.0) 
 
P-cadherin 86 56 (65.1) 30 (34.9) 0.690 
 
52 6 (11.5) 46 (88.5) 0.075
b
 
Positive 52 33 (63.5) 19 (36.5) 
  
33 6 (18.2) 27 (81.8) 
 
Negative 34 23 (67.6) 11 (32.4) 
  
19 0 (0.0) 19 (100.0) 
 
Molecular subtypes 87 57 (65.5) 30 (34.5) 0.226 
 
52 6 (11.5) 46 (88.5) 0.008
b
 
Luminal 60 41 (68.3) 19 (31.7) 
  
36 1 (2.8) 35 (97.2) 
 
HER2-OE 6 2 (33.3) 4 (66.7) 
  
- - - 
 
Triple-negative 21 14 (66.7) 7 (33.3)     16 5 (31.3) 11 (68.8)   
a
 Percentage of row total 
        
b
 Two-sided Fisher's exact test 
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Between each special subtype, there were significant differences in the prevalence of CD44 (p=0.001) 
and ALDH1 (p=0.002) expression, as well as in the prevalence of CD44
+
/CD24
-/low
 phenotype (p=0.002) 
and the combined CD44
+
/CD24
-/low
/ALDH1
+
 phenotype (p=0.042) (table III and IV).  
To explore the differences in the prevalence of expression of these markers between specific special 
subtypes, we compared obtained results with a series previously characterised in our group and 
composed of 465 IDC-NOS characterised for CD44, CD24 and ALDH1, whose results had already been 
published
20
. When grouped together, special subtypes (as one group composed of all tumours in this 
series), 78.2% (68/87) were CD44
+
 and 65.5% (57/87) displayed the CSC phenotype CD44
+
/CD24
-/low
, 
being both results significantly higher that the observed in the IDC-NOS comparison series (both 
p<0.001). And though ALDH1 expression was no different, special subtypes also displayed an enriched 
population with the phenotype CD44
+
/CD24
-/low
/ALDH1
+
 (p=0.043). 
When performing a subgroup analysis by special subtype and comparing to IDC-NOS, several differences 
were found. Regarding CD44 expression, medullary and tubular carcinomas were subtypes enriched in 
this marker (both associations with p<0.001), while regarding CD24 expression, both invasive apocrine 
and papillary carcinomas displayed increased expression in this marker (42.9% and 100% Vs. 11.4% in 
IDC-NOS, with p=0.004 and p<0.001, respectively) (table III).  
Table III – Prevalence of the expression of CD44, CD24  and ALDH1 in the breast cancer histological 
special subtypes 
  
CD 44       CD 24       ALDH1       
  
n 
Positive 
(a) 
Negative 
(a) 
p 
Valueb n 
Positiv
e (a) 
Negative 
(a) 
p 
Valueb n 
Positive 
(a) 
Negative 
(a) p Valueb 
                            
IDC-NOS
c
 
 
463 
237 
(51.2) 226 (48.8) 
 
463 
53 
(11.4) 410 (88.7) 
 
464 33 (7.1) 431 (92,9) 
 
                            
Special subtype 87 
68 
(78.2) 19 (21.8) <0.001 90 
17 
(18.9) 73 (81.1) 0.052 60 8 (13.3) 52 (86.7) 0.119
d
 
mucinous 21 
15 
(71.4) 6 (28.6) 0.069 21 2 (9.5) 19 (90.5) 1.000
d
 19 0 (0.0) 19 (100.0) 0.632
d
 
medullary 15 
15 
(100.0) 0 (0.0) <0.001
d
 15 
3 
(20.0) 12 (80.0) 0.402
d
 12 5 (41.7) 7 (58.3) <0.001
d
 
tubular 
 
14 
14 
(100.0) 0 (0.0) <0.001
d
 14 0 (0.0) 14 (100.0) 0.383
d
 9 0 (0.0) 9 (100.0) 1.000
d
 
invasive apocrine 13 9 (69.2) 4 (30.8) 0.199 14 
6 
(42.9) 8 (57.1) 0.004
d
 - - - 
 
lobular 
 
7 2 (28.6) 5 (71.4) 0.278
d
 7 
2 
(28.6) 5 (71.4) 0.192
d
 5 0 (0.0) 5 (100.0) 1.000
d
 
metaplasic 7 6 (85.7) 1 (14.3) 0.124
d
 8 
2 
(25.0) 6 (75.0) 0.237
d
 9 2 (22.2) 7 (77.8) 0.138
d
 
micropapillary 6 3 (50.0) 3 (50.0) 1.000
d
 6 
2 
(33.3) 4 (66.7) 0.149
d
 1 1 (100.0) 0 (0.0) 0.073
d
 
papillary 4 
4 
(100.0) 0 (0.0) 0.124
d
 5 
5 
(100.0) 0 (0.0) <0.001
d
 5 5 (100.0) 0 (0.0) <0.001
d
 
For comparison of CD44 expression  For comparison of CD24 expression between          For comparison of ALDH1 expression  
between special subtypes: p value = 0.001     special subtypes: p value = 0.090                                 between special subtypes: p value = 0,002 
  
a percentage of raw total                                                                                                                                                 
b
 for comparison with IDC-NOS 
c 
as previously published by Ricardo S et al.
20
 
d
 two-sided Fisher´s exact test 
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Table IV – Prevalence of the expression of CSC phenotype CD44/CD24 and CD44/CD24/ALDH1 in the 
breast cancer histological special subtypes 
  
CD44/CD24       
CSC phenotype 
(CD44/CD24/ALDH1)   
  
n 
CD44+/CD24-/low 
>10% (a) 
CD44+/CD24-/low 
<10% (a) p Valueb n Positive (a) Negative (a) p Valueb 
                    
IDC-NOS
c
 
 
461 209 (45.3) 252 (54.7) 
 
459 22 (4.8) 437 (95.2) 
 
                    
Special subtype 87 57 (65.5) 30 (34.5) <0.001 52 6 (11.5) 46 (88.5) 0.043 
mucinous 21 13 (61.9) 8 (38.1) 0.136 17 0 (0.0) 17 (0.0) 1.000
d
 
medullary 15 12 (80.0) 3 (20.0) 0.008 11 4 (36.4) 7 (63.6) 0.002
d
 
tubular 
 
14 14 (100.0) 0 (0.0) <0.001
d
 10 0 (0.0) 10 (100.0) 1.000
d
 
invasive 
apocrine 13 5 (38.5) 8 (61.5) 0.623 - - - - 
lobular 
 
7 2 (33.3) 4 (66.7) 0.690
d
 5 0 (0.0) 5 (100.0) 1.000
d
 
metaplasic 7 5 (71.4) 2 (28.6) 0.255
d
 7 2 (28.6) 5 (71.4) 0.046
d
 
micropapillary 6 2 (33.3) 4 (66.7) 0.694
d
 1 0 (0.0) 1 (100.0) 1.000
d
 
papillary 4 4 (100.0) 0 (0.0) 0.043
d
 1 0 (0.0) 1 (100.0) 1.000
d
 
For comparison of CD44/CD24 expression between special subtypes, p value =0.002 
For comparison of CSC expression between special subtypes p value =0.042 
a
 percentage of row total 
b
 for comparison with IDC-NOS  
c
 as previously published by Ricardo S et al.
20
 
d
 two-sided Fisher's exact test 
 
Concerning ALDH1 expression and the CSC phenotypes, all tubular (14/14) and papillary (4/4) and 80% 
(12/15) of medullary carcinomas displayed the CD44
+
/CD24
-/low 
phenotype. In all these three subtypes, a 
statistical significant increase was found to IDC-NOS (table 4).  Interestingly, only papillary and medullary 
carcinomas displayed a significant higher proportion of ALDH1 expression. 
Finally, the CD44
+
/CD24
-/low
/ALDH1
+ 
CSC phenotype was observed in 36.4% (4/11) of medullary and 
28.6% (2/7) of metaplasic carcinomas, both special types displaying a statistically significant increase 
(p=0.002 and p=0.046, respectively) over the 4.8% (22/459) prevalence of this CSC phenotype in the 
“control” IDC-NOS series (table IV). 
 
Fig. 1. Immunohistochemical staining of invasive tubular carcinoma for CD44, CD24 and ALDH1. (A) Tubular carcinoma is positive for CD44, 
in more than 50% of neoplastic cells. (B) In contrast, no expression of CD24 is detected. (C) Similarly, no ALDH1 expression is detected in 
tubular carcinoma cells. 
A B C 
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Discussion 
Breast cancer is a heterogeneous 
disease consisting of a growing 
number of biologically distinct 
subtypes with a heterogeneity 
reflected not only by receptor 
expression status but also by 
diverse histological subtypes, as 
well as distinct biological behavior, 
response to therapy and disease 
outcome
1
. 
The present study was design at 
evaluating possible heterogeneity 
in CSC markers according to 
histological special subtypes. To our knowledge, only two studies specifically investigating some of CSC 
markers and histological special subtypes have been published. In one these studies only the expression 
of CD44 is evaluated in micropapillary carcinomas and compared to tubular carcinomas
21
  while in the 
other, although it was investigated the immunophenotype CD44
+
/CD24
-/low
 and results compared to a  
“control” series of IDC-NOS, again, only micropapillary carcinomas were reported
22
. Therefore, our study 
is the first to address the question of CD44, CD24 and ALDH1 CSC markers prevalence, relation to 
pathological features and a series of biomarkers in a cohort with tumors of several different histological 
subtypes. Furthermore, it compares each special subtype represented with previously published data by 
our group of a large cohort of IDC-NOS to explore possible enrichment of these markers in specific 
histological special subtypes.  
 
Regarding specific markers, the CD44 CSC marker is commonly expressed among primary breast 
carcinomas, whereas expression of CD24 and ALDH1 occurs in a minority of cases
19,20,22,25
. Indeed in our 
series, when considering all tumors, although special subtypes displayed similar prevalence to the IDC-
NOS in CD24 and ALDH1 expression, CD44 was more commonly expressed. When combined CSC 
immunophenotypes were assessed, we found in the special subtypes group an increase in the 
prevalence of expression of both CD44
+
/CD24
-/low 
phenotype  and in the CD44
+
/CD24
-/low
/ALDH1
+
 
phenotype. These results strongly contrast with a previous report in which all 9 tumors samples 
usedexpressed the CSC phenotype CD44
+
/CD24
-/low
 
28
. Since then, other groups have reported similar 
prevalence of CD44
+
/CD24
-/low
 tumour cells to the one observed in the present study
22,25,27
, clearly 
demonstrating that not all breast cancers display CD44
+
/CD24
-/low
. One fact that could account for this 
discrepancy is that in Al-Hajj et al. study, the authors used samples from 8 metastasis and only 1 primary 
tumour
28
. 
B A 
C Fig. 2. Immunohistochemical staining of 
medullary carcinoma for CD44, CD24 and 
ALDH1. Similar to tubular carcinoma, 
medullary carcinoma is positive for CD44 
expression, in more than 50% of neoplastic 
cells (A) with no expression of CD24 (B). (C) 
Differently, ALDH1 expression is positive, 
with more than 1% neoplastic cells stained. 
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To correlate markers expression with available pathological variables and biomarkers, all tumors in the 
cohort were considered as a “special subtype” group. In the previous study by our group, CD44 was 
significantly expressed in basal-like tumours and aggressive basal-like cell lines
20
. It has already been 
demonstrated that CD44
+
 cells show a mesenchymal stem cell-like profile, enriched for genes involved in 
cell motility, proliferation and angiogenesis
29
. CD44 expression has also been inversely associated with 
lymph node metastasis
30
. However in this study we fail to reach significance for differences in 
prevalence of CD44 expression for any of the variables studied, namely grade, hormone receptor status, 
HER2 and EGFR receptor status,Ck5, P-caderin, ki-67 proliferation index and molecular subtype.  
Differently, in case of CD24 expression, we found an association with negativity for ER and Her2 
expression, as well as higher prevalence of expression in grade III tumors. In previous studies which 
reported CD24, results were contradictory. While in some no associations were found
20,22
 others have 
associated CD24 expression with higher histological grade
31
 and unfavorable prognosis
32
. These 
contradictory results could, at least partially, be explained by the distinct grading systems used to 
classify CD24 immunohistochemical results
25,27,31,32
, fact that certainly affects the results concerning 
both the identification and the prognostic value of this marker. 
In our study, ALDH1 expression was significantly associated with high grade tumors, ER negativity, PgR 
negativity, triple-negative tumors and with basal marker expression, namely EGFR, CK5 and P-cadherin. 
Similar associations with ALDH1 for IDC-NOS were already described in studies with similar 
methodological approaches by our group
20
 and other authors
19
. 
For the CSC phenotype CD44
+
/CD24
-/low
, in our special subtypes series, the presence of this phenotype 
was only associated with HER2 negative status and higher grade tumours. In the study by Honeth et al. 
in a cohort predominantly composed by IDC-NOS, this CSC phenotype was also correlated with 
low/negative HER2 expression. In the same study this phenotype was further associated with CK5, CK14 
and EGFR expression
25
, and when the authors used the 10% cut-off for tumor cells CD44
+
/CD24
-/low
 (the 
same performed in the present study), they further associated this phenotype with ER negativity. In a 
similar study, the presence of the CSC phenotype CD44
+
/CD24
-/low
 was over associated with negative 
HER2, both in ER positive and ER negative tumours, and a high Ki67 labelling index
19
. In the same study 
this phenotype was not associated with survival, as we and others have also already demonstrated
20,25
. 
Regarding the CD44
+
/CD24
-/low
/ALDH1
+
 phenotype, similar results to the ALDH1 expression were found. 
In case of this CSC phenotype we found associations with both ER and PgR negativity, triple-negative 
tumours and also with the presence of basal markers, namely EGFR and CK5. Similarly the CD44
+
/CD24
-
/low
/ALDH1
+
  phenotype have been associated to worst prognosis in a subgroup of ER negative tumours, 
in contrast with the phenotype defined only by CD44
+
/CD24
-/low
 expression
19
.  
When we performed the analysis by histological special type, both medullary and tubular carcinomas 
were subtypes enriched for CD44 expression. Although this might seem an unexpected result for tubular 
carcinomas, since these tumours are traditionally described as low grade and well differentiated, an 
analogous observation regarding high prevalence of CD44 expression in tubular carcinomas has been 
briefly reported in a study comparing CD44 expression in tubular carcinomas with IMPCs
21
. In that study, 
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the authors report that 96% of tubular carcinomas expressed CD44 in contrast to only 61% of IMPC. In 
the same study, CD44 expression was associated with lymph-node metastasis
21
. Due to these findings, in 
the same article, it is suggested that the loss of CD44s may contribute to reduced cell-cell and cell-
basement membrane adhesion, facilitating detachment of tumour cells from primary sites and 
penetration into lymph-vascular spaces
21
. Nevertheless, the role of CD44 in cancer progression remains 
largely unknown. 
In case of CD24 expression, no differences between special types were found and contrary to a previous 
report of an increased prevalence of CD24 expression in IMPC
22
, in our study and in comparison with 
IDC-NOS, only invasive apocrine and papillary carcinomas displayed a significantly increased expression 
of this marker. Again, although CD24 is known to be involved in cell-cell adhesion and might have an 
important role in the metastatic process
33
, the significance of its expression remains controversial with 
some studies associating it with worse prognosis
27
 while others do not
14
.  
In our series, tubular, papillary and medullary carcinomas were associated with higher prevalence of 
CD44
+
/CD24
-/low
 CSC phenotype. Interestingly some reports mentioned an increased prevalence of this 
phenotype in medullary carcinomas
25
 and in grade I tumours
19
, like the tubular carcinomas. 
Nevertheless in our results we could not confirm the reported enrichment of the CD44
+
/CD24
-/low
 
phenotype in IMPC
22
. 
When investigating the expression of ALDH1 in special subtypes, only papillary and medullary 
carcinomas retained ALDH1 expression, with none of tubular carcinomas expressing it. Therefore, in 
case the combined CSC phenotype CD44
+
/CD24
-/low
/ALDH1
+
, only medullary and metaplasic carcinomas 
demonstrated significant increase in the prevalence of this phenotype over IDC-NOS. Interestingly these 
are two histological subtypes associated with high histological grade and basal-like phenotype. Based on 
these findings we suggest that in case of special subtypes, possibly due to their heterogeneity as a group 
and simultaneous homogeneity of each special subtype, a combination of several markers is essential 
for the identification of tumours that possibly exhibit characteristics traditionally associated with CSC.    
Nonetheless, our study has some potential limitations. First, although our series contained several 
histological subtypes, not all histological subtypes were represented nor its weight on the series was 
adjusted for known prevalence of each of these subtypes. Another limitation when comparing our 
results to other groups is that for the CSC markers used there is no consensus on their evaluation, with 
different groups reporting different grading criteria and cut-offs. Nevertheless, in this study, and as 
already mentioned, we opted to use same methodology as previously used by our group for possible 
comparisons with the previous published IDC-NOS cohort data
20
. 
Other possible limitations of our study could be the assumption of the use of IHC to identify CSC markers 
and the use of TMAs to detect a subpopulation of cells of reputed scarcity; though there are now a 
number of studies that used the same methodologies with robust results
19,20,22,25
 and therefore we do 
not consider the methodology used (TMAs and IHC) as relevant limitations.  
In summary, our analyses should be considered exploratory and it is our conviction that further 
validation studies in independent histological special subtypes cohorts are necessary before definitive 
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conclusions can be drawn. Nevertheless in this study by demonstrating that the prevalence of CSC 
markers is not homogeneous amongst breast cancer histological types and considering that CD44
+
 and 
CD24
+
 cells might represent defined cell populations with distinct genetic profiles
29
, we provide further 
evidence that the several special subtypes are distinguished entities from IDC-NOS also in CSC markers 
expression, fact that should be taken into account in future studies investigating the clinical and 
pathological relevance of CSC markers in breast cancer. Moreover, with our results, we provide 
additional data that supports future use of use a panel of CSC markers, to identify breast CSC in order to 
eventually better identify them and effectively translate knowledge of breast CSCs into clinical benefit. 
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Support Material 
 
 
Supplementary Table 1 - Antibodies used in the immunohistochemistry study 
 
Molecular marker Source Clone Dilution incubation Antigen retrieval Detection reagent 
ER Neomarkers SP1 1:100 1 hr RT Citrate buffer,pH 6  
30 min at 98⁰C 
HRP polymer 
HER-2 Neomarkers SP3 1:80 30 min RT Citrate buffer,pH 6 
30 min at 98⁰C 
SABC 
PgR Novocastra 1A6 1:40 1 hr RT Citrate buffer,pH 6 
30 min at 98⁰C 
HRPpolymer 
P-cadherin BD Transduction 56 1:50 1 hr RT EDTA, pH 8                    
30 min at 98⁰C 
HRP polymer 
CK5 Neomarkers XM26 1:50 1 hr RT EDTA, pH 8                     
30 min at 98⁰C 
SABC 
Ki-67 Neomarkers SP6 1:200 1 hr RT Citrate buffer,pH 6 
30 min at 98⁰C 
HRP polymer 
EGFR Zymed 31G7 1:100 1 hr RT Pepsin                       
30 min at 37⁰C 
SABC 
CD44 Cell signaling 156-3C11 1:100 30 min RT Citrate buffer,pH 6 
30 min at 98⁰C 
SABC 
CD24 Neomarkers SN3b 1:100 1 hr RT Citrate buffer,pH 6 
30 min at 98⁰C 
HRP polymer 
ALDH1 Abcam EP1933Y 1:100 1 hr RT Citrate buffer,pH 6 
30 min at 98⁰C 
HRP polymer 
RT – Room Temperature 
HRP – Horseradish peroxidase 
SABC – Streptavidin-biotin complex 
 
 
 
 
 
 
 
 
 
 
 
 
